Clinical Trial Search

Primary: The Number of Participants With Treatment Emergent Adverse Events of Ampion Compared to Placebo — 5; 9; 3; 5 Participants

Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants

Primary: Number of Subjects With Drug-related Adverse Events (AEs) — 4; 2; 1; 2 Participants

Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 3 Days of N6LS Product Administration Alone or N6LS Co-Administered With rHuPH20 — 3; 1…

Primary: Number of Participants With Solicited Local Adverse Events (AEs) (e.g., Injection Site Pain, Redness, Induration, Swelling) Recorded up to 14 Days After Each Dose of…

Primary: Maximum Observed Plasma Concentration (Cmax) of Sotorasib for Treatments A and B — 6650; 6540 ng/mL

Primary: PK - Cmax — 1102; 282 ng/mL

Primary: Number of Participants Assessed for Safety and Tolerability as Assessed by NCI CTCAE v3.0 — 3; 3; 4; 2 Participants

Primary: Number of Participants With Treatment-emergent Adverse Events — 1; 6; 4; 7 Participants

Primary: Parts 1 and 3: Percentage of Participants With Clinically Significant Physical Examination Findings — 0; 0; 0; 0 percentage of participants

Primary: Number of Participants With Any Medically-attended Adverse Events (MAAEs) — 1; 1; 0; 0 Participants

Primary: Number of Patients With Dose Limiting Toxicities — 0; 0; 0; 0 Participants

Primary: Number of Treatment Related Adverse Events — 3; 4; 0; 3 Number of events

Primary: Number of Participants Experiencing a Dose Limiting Toxicity (Dose Escalation) — 0; 0; 0; 3 Participants

Primary: Maximum Observed Plasma Concentration (Cmax) of Plasma PF-07321332 — 1.886; 1.923 micrograms per milliliter (ug/mL)